Martin Fleisher

18.0k total citations · 4 hit papers
240 papers, 12.4k citations indexed

About

Martin Fleisher is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Martin Fleisher has authored 240 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 87 papers in Oncology and 60 papers in Molecular Biology. Recurrent topics in Martin Fleisher's work include Prostate Cancer Treatment and Research (59 papers), Radiopharmaceutical Chemistry and Applications (32 papers) and Cancer Genomics and Diagnostics (23 papers). Martin Fleisher is often cited by papers focused on Prostate Cancer Treatment and Research (59 papers), Radiopharmaceutical Chemistry and Applications (32 papers) and Cancer Genomics and Diagnostics (23 papers). Martin Fleisher collaborates with scholars based in United States, United Kingdom and Spain. Martin Fleisher's co-authors include Howard I. Scher, Daniel C. Danila, Glenn Heller, Steven M. Larson, Aseem Anand, Johann S. de Bono, Morton K. Schwartz, Hans Lilja, Rita Gonzalez-Espinoza and Richard J. Robbins and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Martin Fleisher

236 papers receiving 12.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

2010 809 citations Howard I. Scher, Tomasz M. Beer et al. The Lancet profile →
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

2007 522 citations Daniel C. Danila, Glenn Heller et al. Clinical Cancer Research profile →
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits

2008 508 citations Martin Fleisher et al. profile →
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

2016 461 citations Howard I. Scher, David Lu et al. profile →

Peers

Countries citing papers authored by Martin Fleisher

Since Specialization

Citations

This map shows the geographic impact of Martin Fleisher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Fleisher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Fleisher more than expected).

Fields of papers citing papers by Martin Fleisher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Fleisher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Fleisher. The network helps show where Martin Fleisher may publish in the future.

Co-authorship network of co-authors of Martin Fleisher

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Fleisher. A scholar is included among the top collaborators of Martin Fleisher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Fleisher. Martin Fleisher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations 2024 ·Gynecologic Oncology Reports ·(unknown), Zvi Yaari, Ron Feiner, (unknown), Arnaud Da Cruz Paula, Pier Selenica, (unknown), S. Dennis, Nadeem R. Abu‐Rustum, Douglas A. Levine, Britta Weigelt, Martin Fleisher, Lakshmi V. Ramanathan, Daniel A. Heller, Kara Long Roche	2
2	Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer 2020 ·Journal of Neuro-Oncology ·Rachna Malani, Martin Fleisher, Priya Kumthekar, Xuling Lin, Antonio Omuro, Morris D. Groves, Nancy U. Lin, Michelle Melisko, Andrew B. Lassman, Suriya Jeyapalan, Andrew D. Seidman, Anna Skakodub, Adrienne Boire, Lisa M. DeAngelis, Marc K. Rosenblum, Jeffrey J. Raizer, Elena Pentsova	62
3	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases 2019 ·Clinical Cancer Research ·Aki Morikawa, Elisa de Stanchina, Elena Pentsova, Margaret Kemeny, Bob T. Li, Kendrick Tang, Sujata Patil, Martin Fleisher, Catherine Van Poznak, Larry Norton, Andrew D. Seidman	35
4	Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer 2017 ·Cancer Research ·Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, Brigit McLaughlin, Adam Jendrisak, Yipeng Wang, Jerry Lee, Stephanie Greene, Rachel Krupa, David Lu, Pascal Bamford, (unknown), Lyndsey Dugan, Hebert Alberto Vargas, Martin Fleisher, Mark Landers, Glenn Heller, Ryan Dittamore	94
5	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer 2016 ·The Oncologist ·Anthony F. Yu, Carlos Manrique, (unknown), Jennifer E. Liu, (unknown), Martin Fleisher, Sujata Patil, Lee W. Jones, Richard M. Steingart, Clifford A. Hudis, Chau T. Dang	38
6	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer 2016 ·European Urology ·David Lorente, David Olmos, Joaquı́n Mateo, Diletta Bianchini, George Seed, Martin Fleisher, Daniel C. Danila, Penny Flohr, Mateus Crespo, Ines Figueiredo, Susana Miranda, Kurt Baeten, Arturo Molina, Thian Kheoh, Robert McCormack, Leon W.M.M. Terstappen, Howard I. Scher, Johann S. de Bono	113
7	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer 2015 ·Journal of Clinical Oncology ·Howard I. Scher, Glenn Heller, Arturo Molina, Gerhardt Attard, Daniel C. Danila, Xiaoyu Jia, Weimin Peng, Shahneen Sandhu, David Olmos, Ruth Riisnaes, Robert G. McCormack, Tomasz Burzykowski, Thian Kheoh, Martin Fleisher, Marc Buyse, Johann S. de Bono	294
8	Interleukin-6 fold change following hepatic artery embolization predicts length of hospital stay 2014 ·Journal of Vascular and Interventional Radiology ·Joseph P. Erinjeri, (unknown), Aliaksandra Samoila, Martin Fleisher, (unknown), Anne M. Covey, Karen T. Brown, George I. Getrajdman, Robert H. Siegelbaum, Jeremy C. Durack, Constantinos T. Sofocleous, Hooman Yarmohammadi, Stephen B. Solomon	1
9	Beneficial effects of perioperative statins for major pulmonary resection 2014 ·Journal of Thoracic and Cardiovascular Surgery ·David Amar, Bernard J. Park, Hao Zhang, Weiji Shi, Martin Fleisher, Howard T. Thaler, Valerie W. Rusch	12
10	Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Nabil P. Rizk, Elliot L. Servais, Laura H. Tang, Camelia S. Sima, Hans Gerdes, Martin Fleisher, Valerie W. Rusch, Prasad S. Adusumilli	35
11	Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors 2012 ·Cancer Research ·Nicholas Mitsiades, Clifford C. Sung, Nikolaus Schultz, Daniel C. Danila, Bin He, Vijay Kumar Eedunuri, Martin Fleisher, Chris Sander, Charles L. Sawyers, Howard I. Scher	175
12	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer 2010 ·Journal of Clinical Oncology ·Daniel C. Danila, Michael J. Morris, Johann S. de Bono, Charles J. Ryan, Samuel R. Denmeade, Matthew R. Smith, Mary-Ellen Taplin, Glenn J. Bubley, Thian Kheoh, Christopher M. Haqq, Arturo Molina, Aseem Anand, (unknown), Steven M. Larson, Lawrence H. Schwartz, Martin Fleisher, Howard I. Scher	318
13	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study breakdown → 2010 ·The Lancet ·Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, Aseem Anand, Mary‐Ellen Taplin, Eleni Efstathiou, Dana E. Rathkopf, Julia Shelkey, Evan Y. Yu, Joshi J. Alumkal, David T. Hung, Mohammad Hirmand, Lynn Seely, Michael J. Morris, Daniel C. Danila, John L. Humm, Steven M. Larson, Martin Fleisher, Charles L. Sawyers	809
14	Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies 2009 ·Journal of Clinical Oncology ·Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, Craig H. Moskowitz, Debra Sarasohn, Ellen Neylon, (unknown), (unknown), Barbara MacGregor‐Cortelli, Molly Bruce Patterson, Venkatraman Seshan, (unknown), Martin Fleisher, Diane R. Mould, M.I. Saunders, Andrew D. Zelenetz	131
15	Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. 2009 ·Oxford University Research Archive (ORA) (University of Oxford) ·(unknown), Jane Han, Zahra Asgari, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Aseem Anand, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I. Scher	11
16	Abstract #5667: ADAMTS1 and MMP1 promote breast cancer bone metastasis through a bone stromal cell-mediated osteolytic signaling cascade 2009 ·Cancer Research ·Xin Lü, Qiongqing Wang, Catherine Van Poznak, Martin Fleisher, Michael Reiß, Joan Massagué, Yibin Kang	2
17	Detection of circulating tumor cells in patients with urothelial cancer 2008 ·Annals of Oncology ·David Gallagher, Matthew I. Milowsky, Nicole Ishill, A. Trout, (unknown), Jamie C. Riches, Martin Fleisher, Dean F. Bajorin	75
18	Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer 2007 ·Clinical Cancer Research ·David R. Shaffer, Margaret Leversha, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Bin Gu, Aseem Anand, Katherine Smith, P. Maslak, Gerald V. Doyle, Leon W.M.M. Terstappen, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I. Scher	284
19	Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity. 2005 ·Blood ·(unknown), Paul A. Hamlin, Ellen Neylon, Craig H. Moskowitz, C. Portlock, (unknown), Ariela Noy, (unknown), Andrew D. Zelenetz, Martin Fleisher, Debra Sarasohn, F. M. Sirotnak, (unknown)	6
20	Dietary manipulation, ethnicity, and serum psa levels 2003 ·Urology ·James A. Eastham, Elyn Riedel, Lianne Latkany, Martin Fleisher, Arthur Schatzkin, Elaine Lanza, Moshe Shike	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact